Prescription pattern of alpha blockers in the treatment of benign prostatic hyperplasia in India: a paper based survey

Simple item page
dc.contributor.authorTomar, Vinayen_US
dc.contributor.authorBhati, Bhoopat Singhen_US
dc.contributor.authorDatta, Biswajiten_US
dc.contributor.authorBellamkonda, Laxmanen_US
dc.contributor.authorPrajapati, Hiren K.en_US
dc.contributor.authorChaturvedi, Aloken_US
dc.contributor.authorDave, Nilanjen_US
dc.contributor.authorJain, Amit B.en_US
dc.date.accessioned2020-04-23T08:00:38Z
dc.date.available2020-04-23T08:00:38Z
dc.date.issued2020-02
dc.description.abstractBackground: Benign prostatic hyperplasia (BPH) is the most common urological condition. The treatment of BPH depends on the severity of symptoms which aims to improve symptoms, lower the risk of progression and improve quality of life. The aim of this survey was to understand the prescription pattern of alpha blockers in the treatment of BPH among clinicians of India.Methods: A cross-sectional questionnaire-based survey was conducted between September to December 2018. Data regarding the management of BPH using ?-blockers were filled by clinicians and collated for data analysis using appropriate statistical test.Results: Total of 1764 clinicians’ responses was collected and the result was analysed. According to the survey, 47.68% of clinicians felt that severity of the BPH symptoms is most common deciding factor for medical management of BPH. For the pharmacological management of BPH patients, around 58% of clinicians opted for ? blockers monotherapy as a preferred option. Among ? blockers, 65.14% of clinicians preferred tamsulosin as first line therapy for management of BPH patients. In this survey, 81.75% of clinicians believed that tamsulosin offers highest persistence rate among commonly prescribed ? blockers. Looking at the switching to a second ?-blocker, 75.45% of clinicians felt that tamsulosin shows the highest return rate following initiation of a second ?-blocker. More than 90% of clinicians felt that favourable efficacy or tolerability of tamsulosin is due to its highest persistence and highest return rates.Conclusions: Tamsulosin is the most commonly preferred and prescribed ?-blocker by Indian clinicians due to its favourable efficacy or tolerability.en_US
dc.identifier.affiliationsUrology Research and Development Centre, SMS Medical College and Hospital, Jaipur, Rajasthan Indiaen_US
dc.identifier.affiliationsDepartment of Urology, Ruby Hall Main Clinic, Pune, Maharashtra, Indiaen_US
dc.identifier.affiliationsDepartment of Urology, North Bengal Medical College, Siliguri, West Bengal, Indiaen_US
dc.identifier.affiliationsHyderabad Urology and Andrology Centre, Hyderabad, Telangana, Indiaen_US
dc.identifier.affiliationsDepartment of Medical Affairs, Intas Pharmaceuticals Limited, Ahmedabad, Gujarat, Indiaen_US
dc.identifier.citationTomar Vinay, Bhati Bhoopat Singh, Datta Biswajit, Bellamkonda Laxman, Prajapati Hiren K., Chaturvedi Alok, Dave Nilanj, Jain Amit B.. Prescription pattern of alpha blockers in the treatment of benign prostatic hyperplasia in India: a paper based survey. International Journal of Basic & Clinical Pharmacology. 2020 Feb; 9(2): 348-352en_US
dc.identifier.issn2319-2003
dc.identifier.issn2279-0780
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/200530
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber2en_US
dc.relation.volume9en_US
dc.source.urihttps://dx.doi.org/10.18203/2319-2003.ijbcp20200189en_US
dc.subjectBenign prostatic hyperplasiaen_US
dc.subjectLower urinary tract symptomsen_US
dc.subject?-blockeren_US
dc.subjectTamsulosinen_US
dc.subjectPersistence rateen_US
dc.subjectReturn rateen_US
dc.titlePrescription pattern of alpha blockers in the treatment of benign prostatic hyperplasia in India: a paper based surveyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijbcp2020v9n2p348.pdf
Size:
468.11 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Basic & Clinical Pharmacology